Barrett's esophagus screening: Difference between revisions
Jump to navigation
Jump to search
m (Categories) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Barrett's esophagus}} | {{Barrett's esophagus}} | ||
{{CMG}}; {{AE}} | |||
==Overview== | |||
Barret's esophagus is a major risk factor for development of esophageal adenocarcinoma. After diagnosis, regular surveillance is needed based on the grade of dyaplasia. | Barret's esophagus is a major risk factor for development of esophageal adenocarcinoma. After diagnosis, regular surveillance is needed based on the grade of dyaplasia. | ||
* Weak recommendation, moderate-quality evidence: screening in patients with multiple risk factors for esophageal adenocarcinoma: | * Weak recommendation, moderate-quality evidence: screening in patients with multiple risk factors for esophageal adenocarcinoma: | ||
# Age: > 50 years old | # Age: > 50 years old | ||
| Line 12: | Line 15: | ||
* Strong recommendation, low-quality evidence: | * Strong recommendation, low-quality evidence: | ||
# Recommend against screening general population with GERD and no risk factors.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |}}</ref> | # Recommend against screening general population with GERD and no risk factors.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |}}</ref> | ||
There is insufficient evidence to recommend routine screening for [disease/malignancy]. | |||
OR | |||
According to the [guideline name], screening for [disease name] is not recommended. | |||
OR | |||
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | |||
==Screening== | ==Screening== | ||
| Line 20: | Line 34: | ||
* High-grade dysplasia in the absence of eradication therapy: 3 months.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref> | * High-grade dysplasia in the absence of eradication therapy: 3 months.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref> | ||
==Screening== | |||
*There is insufficient evidence to recommend routine screening for [disease/malignancy]. | |||
OR | |||
*According to the [guideline name], screening for [disease name] is not recommended. | |||
OR | |||
*According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with: | |||
**[Condition 1] | |||
**[Condition 2] | |||
**[Condition 3] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: (name of the system)]] | |||
Revision as of 19:50, 17 October 2017
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus screening On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus screening |
|
Risk calculators and risk factors for Barrett's esophagus screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Barret's esophagus is a major risk factor for development of esophageal adenocarcinoma. After diagnosis, regular surveillance is needed based on the grade of dyaplasia.
- Weak recommendation, moderate-quality evidence: screening in patients with multiple risk factors for esophageal adenocarcinoma:
- Age: > 50 years old
- Sex: male
- Race: white
- Other: chronic GERD, hiatal hernia, elevated BMI (body mass index),and intraabdominal distribution of body fat.
- Strong recommendation, low-quality evidence:
- Recommend against screening general population with GERD and no risk factors.[1]
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
Weak recommendation, moderate-quality evidence: Endoscopic surveillance in patients with Barrett's esophagus The following intervals are recommended:
- No dysplasia: 3–5 years.
- Low-grade dysplasia: 6–12 months.
- High-grade dysplasia in the absence of eradication therapy: 3 months.[1]
Screening
- There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
- According to the [guideline name], screening for [disease name] is not recommended.
OR
- According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]